AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets

The antioxidant and anti-inflammatory compound AGI-1067 (succinobucol) has potential as an oral anti-diabetic agent. AGI-1067 reduces H(b)A1c, improves fasting plasma glucose, and reduces new-onset diabetes. We investigated AGI-1067 for possible effects on mouse pancreatic islets in vitro. Pretreatment with 10 microM AGI-1067 increased glucose-stimulated insulin secretion (11 mM) without affecting secretion in basal (3 mM) glucose. AGI-1067 enhanced the intracellular calcium response to glucose stimulation in 7 mM and 11 mM glucose, but had no effect in 28 mM or basal glucose. AGI-1067-pretreated islets also showed enhanced calcium responses to methyl pyruvate and alpha-ketoisocaproate at low doses, but not high doses. The AGI-1067-mediated effects on glucose-stimulated calcium were maintained during continuous diazoxide exposure, suggesting effects on the K(ATP)-channel-independent pathway. AGI-1067 also reduced cytokine-induced islet cell death and expression of iNOS, a key component in cytokine signaling. This is the first report of direct stimulatory and protective effects of a first-in-class potential anti-diabetic agent on pancreatic islets.

[1]  I. G. Akmaev,et al.  Role of Antioxidant Enzymes and Antioxidant Compound Probucol in Antiradical Protection of Pancreatic β-Cells during Alloxan-Induced Diabetes , 2004, Bulletin of Experimental Biology and Medicine.

[2]  J. Alexander,et al.  VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[3]  H. Kaneto,et al.  Oxidative Stress and Pancreatic β-Cell Dysfunction , 2005, American journal of therapeutics.

[4]  E. Rojas,et al.  A method for the simultaneous measurement of insulin release and B cell membrane potential in single mouse islets of langerhans , 1981, Diabetologia.

[5]  C. Nunemaker,et al.  Evidence of diminished glucose stimulation and endoplasmic reticulum function in nonoscillatory pancreatic islets. , 2009, Endocrinology.

[6]  J. Lakey,et al.  Human pancreatic islet beta-cell destruction by cytokines is independent of nitric oxide production. , 1994, The Journal of clinical endocrinology and metabolism.

[7]  D. Eizirik,et al.  The role for endoplasmic reticulum stress in diabetes mellitus. , 2008, Endocrine reviews.

[8]  S. Bonner-Weir,et al.  Transcription factor abnormalities as a cause of beta cell dysfunction in diabetes: a hypothesis , 1997, Acta Diabetologica.

[9]  R. Robertson,et al.  β-Cell Glucose Toxicity, Lipotoxicity, and Chronic Oxidative Stress in Type 2 Diabetes , 2004 .

[10]  R. Bertram,et al.  A role for calcium release-activated current (CRAC) in cholinergic modulation of electrical activity in pancreatic beta-cells. , 1995, Biophysical journal.

[11]  P. Berggren,et al.  gamma-tocopherol partially protects insulin-secreting cells against functional inhibition by nitric oxide. , 2000, Biochemical and biophysical research communications.

[12]  D. Mears.  Regulation of Insulin Secretion in Islets of Langerhans by Ca2+Channels , 2004, The Journal of Membrane Biology.

[13]  C. Kunsch,et al.  Selective Inhibition of Endothelial and Monocyte Redox-Sensitive Genes by AGI-1067: A Novel Antioxidant and Anti-Inflammatory Agent , 2004, Journal of Pharmacology and Experimental Therapeutics.

[14]  S. Amiel,et al.  Hypoglycaemia in Type 2 diabetes , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[15]  J. Tardif,et al.  Effects of AGI-1067 and Probucol After Percutaneous Coronary Interventions , 2003, Circulation.

[16]  S. Hazen,et al.  Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. , 2008, Atherosclerosis.

[17]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[18]  Jean-Claude Tardif,et al.  Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[19]  R. Bertram,et al.  Glucose modulates [Ca2+]i oscillations in pancreatic islets via ionic and glycolytic mechanisms. , 2006, Biophysical journal.

[20]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[21]  J. Nadler,et al.  Lisofylline, a Novel Antiinflammatory Agent, Protects Pancreatic β-Cells from Proinflammatory Cytokine Damage by Promoting Mitochondrial Metabolism. , 2002, Endocrinology.

[22]  C. Nunemaker,et al.  A Practical Guide to Rodent Islet Isolation and Assessment , 2009, Biological Procedures Online.

[23]  A. Rabinovitch.  An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. , 1998, Diabetes/metabolism reviews.

[24]  S. Nattel,et al.  Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. , 1997, The New England journal of medicine.

[25]  W. Min,et al.  A Novel Class of Antioxidants Inhibit LPS Induction of Tissue Factor by Selective Inhibition of the Activation of ASK1 and MAP Kinases , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[26]  H. Aburatani,et al.  Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. , 2007, The Journal of clinical investigation.

[27]  A. Kuznetsov,et al.  Defective glucose-dependent endoplasmic reticulum Ca2+ sequestration in diabetic mouse islets of Langerhans. , 1994, The Journal of biological chemistry.

[28]  M. Düfer,et al.  Methyl pyruvate stimulates pancreatic beta-cells by a direct effect on KATP channels, and not as a mitochondrial substrate. , 2002, The Biochemical journal.

[29]  Min Zhang,et al.  Insulin feedback alters mitochondrial activity through an ATP-sensitive K+ channel-dependent pathway in mouse islets and beta-cells. , 2004, Diabetes.

[30]  J. Tardif.  Antioxidants: the good, the bad and the ugly. , 2006, The Canadian journal of cardiology.

[31]  Meng Chen,et al.  Inflammatory Blockade Improves Human Pancreatic Islet Function and Viability , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  C. Wollheim,et al.  Single islet beta‐cell stimulation by nutrients: relationship between pyridine nucleotides, cytosolic Ca2+ and secretion. , 1990, The EMBO journal.

[33]  C. Kunsch,et al.  Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. , 2002, Bioorganic & medicinal chemistry letters.

[34]  R. Stocker.  Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues , 2009, Current opinion in lipidology.

[35]  N. Welsh,et al.  Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Myriam Nenquin,et al.  In vivo and in vitro glucose-induced biphasic insulin secretion in the mouse: pattern and role of cytoplasmic Ca2+ and amplification signals in beta-cells. , 2006, Diabetes.

[37]  I. Chang,et al.  Death effectors of β-cell apoptosis in type 1 diabetes , 2004 .

[38]  H. Kaneto,et al.  Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. , 2002, Diabetes research and clinical practice.

[39]  F. Ortis,et al.  Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. , 2005, Diabetes.

[40]  I. G. Fantus,et al.  Free Fatty Acid–Induced Reduction in Glucose-Stimulated Insulin Secretion , 2007, Diabetes.

[41]  R. Alexander,et al.  AGI-1067: A Multifunctional Phenolic Antioxidant, Lipid Modulator, Anti-Inflammatory and Antiatherosclerotic Agent , 2003, Journal of Pharmacology and Experimental Therapeutics.

[42]  S. Kyuwa,et al.  Protective effects of probucol treatment on pancreatic beta-cell function of SZ-induced diabetic APA hamsters. , 2003, Experimental animals.

[43]  S. G. Laychock,et al.  A protective role for heme oxygenase expression in pancreatic islets exposed to interleukin-1beta. , 1998 .

[44]  B. Soria,et al.  Glucoseminduced [Ca2+]i oscillations in single human pancreatic islets , 1996 .

[45]  T. Ogihara,et al.  Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice. , 1995, Biochemical and Biophysical Research Communications - BBRC.

[46]  C. Kunsch,et al.  Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases. , 2004, Journal of medicinal chemistry.

[47]  A. Drash,et al.  Effect of probucol on development of diabetes mellitus in BB rats. , 1988, The American journal of cardiology.

[48]  J. Henquin,et al.  The K+-ATP channel-independent pathway of regulation of insulin secretion by glucose: in search of the underlying mechanism. , 1998, Diabetes.

[49]  Meng Chen,et al.  12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet. , 2008, American journal of physiology. Endocrinology and metabolism.

[50]  L. Harrison,et al.  IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans. , 1988, Journal of immunology.

[51]  J. Nerup,et al.  Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. , 1987, Journal of immunology.

[52]  M. Dunne,et al.  Glucose activates both K(ATP) channel-dependent and K(ATP) channel-independent signaling pathways in human islets. , 1998, Diabetes.

[53]  J. C. James,et al.  Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding. , 2002, The Journal of biological chemistry.

[54]  Joseph L Evans,et al.  Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. , 2002, Endocrine reviews.

[55]  L. Satin,et al.  Insulin secretion in the conscious mouse is biphasic and pulsatile. , 2006, American journal of physiology. Endocrinology and metabolism.

[56]  C. Zoccali,et al.  Endothelial Dysfunction and C-Reactive Protein Are Risk Factors for Diabetes in Essential Hypertension , 2008, Diabetes.

[57]  M. Komatsu,et al.  Importance of nonionic signals for glucose-induced biphasic insulin secretion. , 2002, Diabetes.

[58]  J. Henquin,et al.  Triggering and amplifying pathways of regulation of insulin secretion by glucose. , 2000, Diabetes.